Twitter feed

13th July 2022

Invizius, a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, is pleased to announce the appointment of Professor Peter Stenvinkel (pictured right) to its Clinical Advisory Board. Professor Stenvinkel is a world-renowned expert senior lecturer at Karolinska University Hospital and Professor of Nephrology at Karolinska Institutet (KI), Stockholm, Sweden.

26th April 2022

Invizius, a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant from Innovate UK to research a new field of application for its H-Guard® technology. The company will assess in-vitro and in-vivo efficacy of a novel method of using its technology for Peritoneal Dialysis and progress thereafter into pre-clinical development.

30th March 2022

Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of haemodialysis, to the clinic. The funds will be used towards H-Guard’s First-in-Man safety study commencing in 2022.

6th May 2021

Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of £5.3 million. The financing was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. Although already over-subscribed, the company’s Series A remains open to other investors until June 2021.

Feb. 2020     

Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank.

Jan. 2020     

Invizius, the University of Edinburgh spin-out which is developing potentially lifesaving products for dialysis patients, has made four high-profile appointments as it prepares to enter the next stage of its development.

Oct. 2019     

Invizius, the Univerity of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75m from a consortium of investors.

Feb. 2019

Invizius has been named by FierceMedTech as one of 2018’s Fierce 15 med tech companies, designating it as one of the most promising private companies in the industry.

Oct. 2018

Invizius has been named Best Innovative MedTech company at the prestigious OBN Awards.

Apr. 2018

University of Edinburgh spinout, Invizius, has secured £0.5m seed investment from Mercia Fund Managers.